Cybrexa Therapeutics
Erling Emerson's work experience includes serving as a Research Scientist at Cybrexa Therapeutics since July 2019. Prior to that, they worked at Novartis as a Scientist II from November 2009 to January 2015. Erling also had an extensive tenure at Pfizer Global Research and Development, Pfizer Inc., where they held the role of Scientist from February 1998 to March 2009. Additionally, Erling worked at Pfizer as a Scientist from 1998 to 2009 and at Cephalon Inc. as an Associate Scientist IV from 1995 to 1998.
Erling Emerson has a BS degree in Biochemistry from Marlboro College. Additionally, Erling has pursued an MS degree in Micro/molecular biology from Duquesne University. However, no specific start or end years were provided for either educational experience.
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.